Glasses for Adolescent Delayed Sleep-Wake Phase Disorder

Delayed Sleep-Wake Phase Disorder Clinical Trial

Official title:

Glasses for Adolescent Delayed Sleep-Wake Phase Disorder (GLAD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04378933
• Other study ID #: 18-003036
• Status: Completed
• Phase: N/A
• Start date: February 27, 2019
• Est. completion date: June 3, 2022

Study information

• Verified date: May 2023
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if evening amber glasses combined with stable wake times will show an increase in total sleep time (TST) and an advance in sleep onset times (shift earlier) compared to the control group.

Description:

We propose a 3-week field study that examines the efficacy, acceptance, and compliance of using evening amber glasses to block evening light combined with a stable wake time in adolescents (14-17 years) with DSWPD (International Classification of Sleep Disorders [ICSD-3] criteria).3 After 1 week of baseline measurements, subjects will be instructed to wear glasses (which allow 14% entry of ambient light exposure) starting 7 h before individually calculated midsleep time measured during the preceding week. This corresponds to the time when adolescents are most sensitive to phase delaying light according to Co-I Crowley's recently published phase response curve (PRC) to light in adolescents (Figure 1).22 This "amber glasses + stable wake time" group will be compared to a control group: adolescent DSWPD patients who will wear clear-lensed glasses (which allow 100% of ambient light to reach the eyes, otherwise identical in appearance) in the evening at the same times as the alternate group, but without scheduled wake times. Outcome measures will include TST and sleep onset time derived from wrist actigraphy, daytime subjective sleepiness, salivary DLMO, and assessments of acceptance and compliance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: June 3, 2022
• Est. primary completion date: June 3, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 14 Years to 17 Years

Eligibility

Inclusion Criteria

• Regular school attendance in the setting of a fixed start time.

• Adherence to ICSD-3 DSWPD diagnostic criteria.

• Average spontaneous weekend wake time =1 hour than school day wake time.

• Initiation of school-night sleep at 12 a.m. or later, =50% of the time, during a 14-day period (items 3-4 to be determined by sleep logs and actigraphy). As there are no discrete clock times associated with the ICSD-3 DSWPD description, this cutoff is based on data obtained from the 2006 Sleep in America Poll and experiences gleaned from prior recruitment.

Exclusion Criteria

• A positive urine drug abuse screen will disqualify the individual from further participation.

• Subjects will be withdrawn from the study if the sleep log and wrist monitor activity does not correspond with the sleep schedule identified with the pre-study sleep log.

• Alcohol and nicotine use will also be screened to qualify for the study. We will also screen for alcohol immediately before each DLMO assessment because alcohol acutely suppresses melatonin.

• Patients receiving medications that might contribute to sleep disturbances and/or affect treatment responses will be considered ineligible (e.g., hypnotics, antidepressants, stimulants, non-steroidal anti-inflammatory drugs (NSAIDs), beta blockers).

• All subjects will be asked to refrain from caffeine use on the days of phase assessments, and to cease ingestion at least 6 hours prior to nightly bedtime.

• The Ishihara Color Blindness Test will be done and patients who are color blind/deficient will be disqualified from participating in the study.

Related Conditions & MeSH terms

• Delayed Sleep-Wake Phase Disorder
• Sleep Disorders, Circadian Rhythm

Intervention

Device:
• Amber Glasses
Half of the participants will be wearing the amber glasses to see if they can help with sleep onset.
• Clear Lens Glasses
Half of the participants will be wearing the clear glasses to see if the glasses help with sleep onset.

Locations

Country	Name	City	State
United States	Rush University Medical Center	Chicago	Illinois
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in School Night Sleep Onset Time	The time in hours that sleep onset time shifted earlier during school nights. Measured by self-reporting logs and a wrist actigraphy that detects when subjects are active or sleeping.	baseline, week 3
Primary	Change in Non-school Night Sleep Onset Time	The time in hours that sleep onset time shifted earlier during non-school nights. Measured by self-reporting logs and a wrist actigraphy that detects when subjects are active or sleeping.	baseline, week 3
Primary	Change in Dim Light Melatonin Onset (DLMO)	The time of day the subject feels sleepy during the overnight lab stays. It is a marker of biological time. Data are provided in decimal and military time (e.g., 10:00 pm equals 22.00).; Using a light lux meter, the lighting in the room was limited to no more than 5 lux of light. Measured by self-reported logs and a wrist actigraphy that detects when subjects are active or sleeping.	baseline, week 3
Primary	Change in Dim Light Melatonin Onset (DLMO) Phase Shift	The time in hours the circadian clock shifted the sleep onset time. Using a light lux meter, the lighting in the room will be limited to no more than 5 lux of light. Measured by self-reported logs and a wrist actigraphy that detects when subjects are active or sleeping.	baseline, week 2

External Links

•   Mayo Clinic Clinical Trials